Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: PF-04958242
Drug: Placebo

First Posted Date: 2010-11-10

Last Posted Date: 2019-12-24

Lead Sponsor: Biogen

Target Recruit Count: 20

Registration Number: NCT01238679

Locations: 🇸🇬
Research Site, Singapore, Singapore

Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: BIIB041 (Fampridine-SR)

First Posted Date: 2010-11-05

Last Posted Date: 2014-07-04

Lead Sponsor: Biogen

Target Recruit Count: 38

Registration Number: NCT01235221

Locations: 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦
Ottawa Hospital General Campus, Ottawa, Ontario, Canada
🇨🇦
Foothills Medical Center, Calgary, Alberta, Canada

and more 2 locations

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIB041 (Fampridine-PR)

First Posted Date: 2010-10-06

Last Posted Date: 2014-07-09

Lead Sponsor: Biogen

Target Recruit Count: 36

Registration Number: NCT01215084

Locations: 🇭🇰
Research Site, Shatin, Hong Kong

Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2010-09-29

Last Posted Date: 2014-06-09

Lead Sponsor: Biogen

Target Recruit Count: 301

Registration Number: NCT01211678

Locations: 🇺🇸
Research Site, Franklin, Wisconsin, United States

Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)

Phase 4

Terminated

Conditions: Leukoencephalopathy, Progressive Multifocal
Immune Reconstitution Inflammatory Syndrome

Interventions: Drug: Methylprednisolone
Drug: Prednisolone

First Posted Date: 2010-09-29

Last Posted Date: 2014-09-05

Lead Sponsor: Biogen

Target Recruit Count: 3

Registration Number: NCT01211665

Locations: 🇩🇪
Research Site, Wurzburg, Germany

Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

Terminated

Conditions: Progressive Multifocal Leukoencephalopathy

First Posted Date: 2010-09-29

Last Posted Date: 2015-01-19

Lead Sponsor: Biogen

Target Recruit Count: 24

Registration Number: NCT01211639

Locations: 🇺🇸
Central Neurology, Hastings, Nebraska, United States
🇺🇸
North Central Neurology Associates, Cullman, Alabama, United States
🇺🇸
Rocky Mountain MS Center at Anschutz Medical Campus University Colorado Denver, Aurora, Colorado, United States

and more 7 locations

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2010-08-20

Last Posted Date: 2014-06-02

Lead Sponsor: Biogen

Target Recruit Count: 7726

Registration Number: NCT01185717

Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

Phase 1

Withdrawn

Conditions: Secondary Progressive Multiple Sclerosis

First Posted Date: 2010-08-13

Last Posted Date: 2013-09-16

Lead Sponsor: Biogen

Registration Number: NCT01181089

Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Avonex

First Posted Date: 2010-08-13

Last Posted Date: 2013-09-16

Lead Sponsor: Biogen

Target Recruit Count: 60

Registration Number: NCT01181115

Locations: 🇨🇳
Research Site, Xi'an, China

First-in-Human Study of PF-04958242 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: PF-04958242
Drug: Placebo

First Posted Date: 2010-07-09

Last Posted Date: 2019-12-24

Lead Sponsor: Biogen

Target Recruit Count: 24

Registration Number: NCT01159483

Locations: 🇸🇬
Research Site, Singapore, Singapore

Home Terms & Conditions Privacy Policy